RNA-seq of C3H/HeJ AA mice skin biopsies treated with JAK-selective inhibitors

To define the molecular response to JAKi treatment, we performed RNA-seq analysis on a series of skin biopsies taken before and after systemic treatment with INCB039110 (JAK1i), CEP-33779 (JAK2i), PF-06651600 (JAK3i), ruxolitinib (JAK1/2i), tofacitinib (pan-JAKi) or vehicle control. Overall design: mRNA profiles to JAKi treatment of C3H/HeJ AA mice.

为明确Janus激酶抑制剂（JAKi）治疗诱导的分子应答，我们对经INCB039110（JAK1抑制剂，JAK1i）、CEP-33779（JAK2抑制剂，JAK2i）、PF-06651600（JAK3抑制剂，JAK3i）、芦可替尼（JAK1/2抑制剂，JAK1/2i）、托法替布（泛JAK抑制剂，pan-JAKi）或赋形剂对照进行全身给药治疗前后采集的一系列皮肤活检组织开展了RNA测序（RNA-seq）分析。本实验总体设计为：解析C3H/HeJ AA小鼠接受JAKi治疗后的mRNA表达谱。